As of 2025-05-20, the Intrinsic Value of Enlivex Therapeutics Ltd (ENLV) is -5.65 USD. This ENLV valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.99 USD, the upside of Enlivex Therapeutics Ltd is -670.78%.
Based on its market price of 0.99 USD and our intrinsic valuation, Enlivex Therapeutics Ltd (ENLV) is overvalued by 670.78%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.65 - -5.65 | -5.65 | -670.78% |
| P/E | (0.90) - (1.22) | (1.05) | -205.6% |
| DDM - Stable | (6.17) - (16.51) | (11.34) | -1245.7% |
| DDM - Multi | (0.05) - (0.11) | (0.07) | -107.4% |
| Market Cap (mil) | 21.77 |
| Beta | 1.12 |
| Outstanding shares (mil) | 21.99 |
| Enterprise Value (mil) | 19.00 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.49% |
| Cost of Debt | 5.00% |
| WACC | 8.58% |